Trihexyphenidyl is an antispasmodic drug used to treat stiffness, tremors, spasms, and poor muscle control. It is an agent of the antimuscarinic class and is often used in management of Parkinson's disease. It was approved by the FDA for the treatment of Parkinsonian syndromes and drug-induced extrapyramidal disorders. Mechanistically it acts as a centrally acting muscarinic acetylcholine receptor antagonist with higher functional impact on tremor and rigidity than on bradykinesia, is a lipophilic tertiary amine that readily crosses the blood brain barrier, and is commonly formulated as the hydrochloride salt for oral immediate release administration. Key pharmaceutical attributes include routine assay by reversed-phase HPLC with typical purity specifications in the high 90s percent range, control of related substances by validated LC methods, and characterization of pharmacokinetics showing rapid oral absorption with Tmax generally within 1 to 2 hours, a relatively short elimination half-life on the order of several hours, and hepatic metabolism with renal excretion of metabolites.
Parent: Trihexyphenidyl
Parent: Trihexyphenidyl/ Trihexyphenidyl Hydrochloride
Parent: Trihexyphenidyl
Parent: Trihexyphenidyl
Typical impurity and related-compound control for trihexyphenidyl focuses on synthetic by-products, N-dealkylated species, N-oxide derivatives, ring-opened or partially hydrogenated piperidyl fragments, and residual solvents or catalysts from manufacture; analytical control is performed by HPLC and LC-MS for related substances and by GC for volatile impurities. Typical in-house specification ranges used by manufacturers are assay 98.0 to 102.0 percent, individual related-compound limits commonly set between 0.1 and 0.5 percent depending on identification and toxicology qualification, and total unspecified impurities typically controlled below 2.0 percent in the final API. Residual solvent limits are aligned with ICH Q3C guidance, for example methanol and dichloromethane monitored to their respective permissible ppm levels, and inorganic residues such as heavy metals are controlled to pharmacopeial limits. All impurity profiles should be referenced to validated analytical methods and any impurity above reporting or qualification thresholds must be identified and qualified per regulatory guidance.
Trihexyphenidyl is used to reduce Parkinsonian features such as tremor and muscle rigidity and to treat drug-induced extrapyramidal symptoms caused by certain antipsychotic medications; it is prescribed as part of symptomatic management rather than as a disease modifying therapy.
No, trihexyphenidyl is not an antipsychotic; it is an antimuscarinic antispasmodic used to treat movement disorders and to counteract extrapyramidal side effects of antipsychotic drugs.
In mental health settings trihexyphenidyl is primarily used to manage antipsychotic-induced extrapyramidal symptoms such as acute dystonia and parkinsonism; it does not treat core psychiatric symptoms but can improve tolerability of antipsychotic therapy by reducing motor side effects.
Sedation or drowsiness can occur with trihexyphenidyl because central anticholinergic activity may produce somnolence; patients may also experience other anticholinergic effects such as dry mouth, blurred vision, constipation, and cognitive slowing, so caution is advised when initiating therapy or combining with other sedating agents.
